EVMN Evommune, Inc. Loading...

Loading chart...
Top Calls

No data yet

Price change since each call, adjusted for long/short direction. Results calculated:

Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
Time Author Thesis Company / ticker Signal Since call Position Source
13:52
Jun 29
Martin Shkreli
Buy EVMN on the dip following a drug failure, as the overhang clears and market attention can.
Buy EVMN on the dip following a drug failure, as the overhang clears and market attention can now re-rate the IL-18 program, a potentially differentiated asset in the autoimmune space.
EVMN Evommune, Inc. Long 1ST — —

About EVMN Investor Commentary

Across the available history and selected sources, Buzzberg tracks EVMN (Evommune, Inc.) across 5 sources: 1 bullish vs 0 bearish calls from 5 authors. Historical directional balance: 17% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 6 total trade ideas tracked. Latest voices: Martin Shkreli.